Treatment of Lean MASLD
Lean MASLD should be treated with the same evidence-based approach as non-lean MASLD: lifestyle modification as the cornerstone (targeting ≥5-7% weight loss even in lean patients), with resmetirom for those with stage F2-F3 fibrosis if locally approved, and semaglutide as an alternative FDA-approved option for MASH with moderate-to-advanced fibrosis. 1, 2
Key Principle: Lean MASLD is High-Risk Despite Lower BMI
While lean MASLD patients have fewer cardiometabolic comorbidities than their non-lean counterparts, they paradoxically face higher rates of advanced fibrosis and all-cause mortality 3, 4. This makes aggressive treatment essential despite the "lean" phenotype. The thin-fat phenotype common in lean MASLD (increased visceral adiposity, insulin resistance) drives disease progression similarly to non-lean disease 3.
Treatment Algorithm
First-Line: Lifestyle Modification (All Patients)
Even in lean patients, lifestyle changes remain the cornerstone 1:
- Weight loss targets: ≥5% to improve steatosis, ≥7-10% to improve inflammation and fibrosis 5
- Diet: Mediterranean or similar plant-based diets 5
- Exercise: ≥150 minutes/week of moderate aerobic activity plus resistance training (effective independent of weight loss) 5
- Alcohol: Discourage consumption; complete abstinence if significant fibrosis present 1
- Coffee: Associated with improved liver outcomes in observational studies 1
Pharmacotherapy: Stage-Based Approach
For Non-Cirrhotic MASH with Stage F2-F3 Fibrosis:
Resmetirom (if locally approved): Strong recommendation for MASH-targeted therapy demonstrating histological efficacy on steatohepatitis and fibrosis with acceptable safety profile 1. This is the primary MASH-targeted therapy endorsed by EASL-EASD-EASO guidelines.
Semaglutide 2.4 mg/week (Wegovy®): FDA-approved August 2025 for MASH with F2-F3 fibrosis based on ESSENCE trial showing MASH resolution (62.9% vs 34.3% placebo) and fibrosis improvement (36.8% vs 22.4% placebo) 2. Use noninvasive tests for patient selection rather than biopsy.
For Patients with Comorbidities:
GLP-1 receptor agonists (semaglutide, tirzepatide): Should be used for their approved indications (T2D, obesity) as they improve cardiometabolic outcomes and are safe in MASH 1. While not formally recommended as MASH-targeted therapy by guidelines, substantial weight loss from GLP-1RAs could provide histological benefit 1.
SGLT2 inhibitors: Safe in MASLD, use for approved indications (T2D, heart failure, CKD) 1.
Pioglitazone: Safe in non-cirrhotic MASH but cannot be recommended as MASH-targeted therapy due to lack of phase III efficacy data 1.
What NOT to Use:
- Vitamin E: Cannot be recommended despite prior interest, due to lack of robust phase III data and potential long-term risks 1
- Metformin: Insufficient evidence as MASH-targeted therapy 1
- Non-incretin weight-loss agents: Not recommended 1
Surgical Options
Bariatric surgery: Should be considered in lean MASLD patients who meet approved indications, as it induces long-term liver benefits and cardiometabolic improvements 1. This may be particularly relevant for lean patients with visceral adiposity and metabolic dysfunction.
Critical Caveats for Lean MASLD
Don't underestimate risk: The "lean" label is misleading—these patients have higher mortality and advanced fibrosis rates than expected 3, 4
Sarcopenia screening: Commonly coexists in lean MASLD; resistance training becomes even more critical 3
Visceral fat is the target: Even without high BMI, visceral adiposity drives disease—body composition matters more than weight alone 3
No cirrhotic-stage pharmacotherapy: Neither resmetirom nor other MASH-targeted drugs are recommended for cirrhotic-stage disease 1
Monitoring on semaglutide: Watch for lean mass loss, GI symptoms, gallbladder disease, and rare complications (pancreatitis, retinopathy progression) 2
Practical Implementation
Use noninvasive tests for fibrosis staging rather than biopsy 2:
- VCTE: 8-15 kPa suggests F2-F3
- MRE: 3.1-4.4 kPa suggests F2-F3
- ELF: 9.2-10.5 suggests F2-F3
For borderline cases (VCTE 15-20 kPa), use confirmatory testing and exclude cirrhosis before initiating pharmacotherapy 2.
Treatment response monitoring (at 72 weeks) 2:
- ALT reduction >17 U/L or ≥20%
- CAP reduction ≥30%
- VCTE LSM reduction ≥30%
- MRE LSM reduction ≥20%